Introduction Licensing Opportunities in Cancer provides you with the 35 most promising oncology licensing candidates. To place these in context, the cancer market size and forecast overall growth to 2016 are detailed. The report also presents the epidemiology for major cancers, with forecasts to 2020. Analysis of deal trends offers insight into typical deal values and milestone payments in the oncology space. Scope of this research Which Phase II oncology drugs have been identified by our panel of experts as having the greatest licensing potential? What is the forecast size of the cancer market in 2016? Which drugs currently lead the oncology market? To what extent have biomarkers been explored or used during clinical development of the profiled drugs?
Research and analysis highlights In addition to identification of the top 35 licensing opportunities from hundreds of candidates, the report enables you to explore a development overview of each profiled drug. The overview contains: target and mechanism of action, therapeutic modality, clinical trial history, biomarkers, competitive landscape, orphan designation. Analysis of the market potential in terms of both incidence and company-reported sales. Key reasons to purchase this research Evaluate licensing trends associated with deal making and acquisitions in the oncology area through trend analysis. Identify the most promising drugs in Phase II for oncology, with coverage of mechanism of action, structure, trial history, and competitive landscape. Examine the market dynamics of novel drug development in oncology. Assess licensing trends through an overview of licensing deal milestones and payment terms for the past ten years.
Contains 160 pages and 131 tables/figures.
|